Introduction
non-dialysis CKD anemia, CKD, impaired kidney function, anemia, kidney injury, albuminuria
ANEMIA, CHRONIC KIDNEY DISEASE (CKD), COMPLICATIONS
Chronic kidney disease (CKD) is a progressive illness defined by impaired kidney function, as measured using the estimated glomerular filtration rate (eGFR), albuminuria thresholds, or kidney injury duration [Erythropoietin synthesis is directly affected by impaired kidney function in patients with CKD, which limits hemoglobin (Hb) production, leading to serious complications such as anemia. The average prevalence of anemia is approximately twice as high in patients with CKD than in the general population [Two randomized, parallel-group, open-label, multicenter trials in Japan have shown that molidustat, a novel inhibitor of hypoxia-inducible factor-prolyl hydroxylase (HIF-PH), is efficacious and safe for treating non-dialysis CKD anemia as an alternative to a conventional ESA such as darbepoetin alfa [This post-hoc analysis aimed to evaluate the changes in TSQM-II domain scores relative to baseline in each trial, to assess patient satisfaction with molidustat versus darbepoetin alfa.